Log In
Print this Print this

mericitabine (RG7128, RO5024048) (formerly R7128)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionProdrug of PSI-6130, a cytidine nucleoside analog non-structural protein 5B (NS5B) polymerase inhibitor
Molecular Target HCV NS5B polymerase
Mechanism of ActionNucleoside analog polymerase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotype 1 infection in patients who failed previous therapy; Treat chronic HCV genotype 1 infection; Treat chronic hepatitis C virus (HCV) genotype 1 or 4 infection in treatment-naïve patients; Treat chronic hepatitis C virus (HCV) infection
Regulatory Designation U.S. - Fast Track (Treat chronic hepatitis C virus (HCV) infection)
Partner Chugai Pharmaceutical Co. Ltd.; Roche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today